financetom
Business
financetom
/
Business
/
Water pump maker Gorman-Rupp misses Q3 profit estimates on higher costs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Water pump maker Gorman-Rupp misses Q3 profit estimates on higher costs
Oct 24, 2025 4:03 AM

Overview

* Gorman-Rupp ( GRC ) Q3 revenue rose 2.8% but missed analyst expectations

* Adjusted EPS for Q3 missed analyst estimates

* Adjusted EBITDA for Q3 beat analyst expectations

* Company optimized facilities to reduce costs and support growth markets

Outlook

* Company expects effective tax rate for 2026 to be between 21.0% and 23.0%

* Gorman-Rupp ( GRC ) sees strong incoming orders and increasing backlog for 2025 and 2026

Result Drivers

* FACILITY OPTIMIZATION - Co reduced NPC facilities to lower fixed costs and support growth in fire, municipal, and HVAC markets

* MARKET DEMAND - Increased sales in industrial and municipal markets due to data center demand and infrastructure investment

* COST IMPACT - Facility optimization and material costs contributed to decreased gross and operating margins

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $172.80 $174.60

Revenue mln mln (2

Analysts

)

Q3 Miss $0.52 $0.56 (2

Adjusted Analysts

EPS )

Q3 EPS $0.43

Q3 Net $11.30

Income mln

Q3 Beat $32.29 $31.50

Adjusted mln mln (1

EBITDA Analyst)

Q3 Gross 29.20%

Margin

Q3 Gross $50.40

Profit mln

Q3 $21.50

Operatin mln

g Income

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy."

* Wall Street's median 12-month price target for Gorman-Rupp Co ( GRC ) is $55.00, about 10.7% above its October 23 closing price of $49.12

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Apr 29, 2026
April 29 (Reuters) - Italy's Chiesi has agreed to buy KalVista Pharmaceuticals ( KALV ) for about $1.9 billion, the company said on Wednesday, as it looks to grow its rare disease drug portfolio. ...
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
Apr 29, 2026
April 29 (Reuters) - AbbVie ( ABBV ) on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to navigate its transition away from its once-blockbuster drug, Humira. The company has been leaning heavily on Skyrizi and Rinvoq to fill the void left by Humira, which lost U.S....
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
Apr 29, 2026
April 29 (Reuters) - AbbVie ( ABBV ) on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to navigate its transition away from its once-blockbuster drug, Humira. The company has been leaning heavily on Skyrizi and Rinvoq to fill the void left by Humira, which lost U.S....
Canadian National Railway's Q1 Adjusted EPS, Revenue Decline
Canadian National Railway's Q1 Adjusted EPS, Revenue Decline
Apr 29, 2026
07:50 AM EDT, 04/29/2026 (MT Newswires) -- Canadian National Railway ( CNI ) reported Q1 adjusted earnings Wednesday of 1.80 Canadian dollars ($0.79) per diluted share, compared with CA$1.85 a year earlier. Analysts surveyed by FactSet expected CA$1.80. Revenue for the quarter ended March 31 was CA$4.38 billion, compared with CA$4.40 billion a year earlier. Analysts surveyed by FactSet expected...
Copyright 2023-2026 - www.financetom.com All Rights Reserved